BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER

Clinical trials for BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER explained in plain language.

Never miss a new study

Get alerted when new BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER trials appear

Sign up with your email to follow new studies for BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Completed 1

New cocktail shows promise against Tough-to-Treat colon cancer

Disease control Completed

This phase 2 trial tested a combination of three drugs—encorafenib, binimetinib, and cetuximab—in 95 patients with a specific type of advanced colorectal cancer (BRAF V600E mutation) who had not received prior treatment for their metastatic disease. The goal was to see how many p…

Matched conditions: BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER

Phase: PHASE2 • Sponsor: Pierre Fabre Medicament • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC

BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER

Get alerted when new BRAF V600E-MUTANT METASTATIC COLORECTAL CANCER trials appear

New cocktail shows promise against Tough-to-Treat colon cancer